Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Oncolytics Biotech reported that its oncolytic virus pelareorep, when paired with RAS‑targeted inhibitors, produced markedly stronger anti‑tumor effects in a solid‑tumor preclinical model. The company will extend this work to pancreatic ductal adenocarcinoma and colorectal cancer, testing KRAS G12C, pan‑RAS and next‑generation RAS pathway agents. These data suggest pelareorep can act as an immune‑priming backbone for targeted therapies. Full results are slated for presentation in the fall or winter of 2026.
‘King Keytruda’s Reign Continues.’ Investors Aren’t Wowed by a Promising New Lung Cancer Drug.
A late‑stage trial of ivonescimab, a novel lung‑cancer therapy developed by China’s Akeso and licensed to U.S. firm Summit Therapeutics, showed a 34% reduction in overall mortality compared with the control drug. The data met the primary overall‑survival endpoint in...
Laverock Therapeutics Awarded £2.2m Through Innovation Grants
Laverock Therapeutics has secured more than £2.2 million (approximately $2.8 million) in two competitive innovation grants to accelerate its programmable gene‑control platform. The first grant will fund scaling of a T‑cell product pipeline focused on solid‑tumour cancers, leveraging patient datasets and intracellular...
2026 Orphan Drugs Report: A Safe(r) Passage Amid Stormy Waters?
Orphan drug sales are on a steady climb, projected to represent over 21% of global prescription drug revenue by 2032—about $400 billion of an estimated $2 trillion market. The top eight orphan products will each exceed $6 billion in sales, with Darzalex leading...
Eli Lilly Highlights P-III (LIBRETTO-432) Trial Data on Retevmo for Early-Stage RET Fusion–Positive NSCLC at ASCO 2026
Eli Lilly presented data from its phase III LIBRETTO‑432 trial of selpercatinib (Retevmo) as adjuvant therapy in early‑stage RET‑fusion positive NSCLC. In 151 patients, the drug reduced the risk of disease recurrence or death by 83% versus placebo, with 24‑month...
Akeso Presents the P-III (HARMONi-6) Trial Data on Ivonescimab + CT in 1L Squamous NSCLC at ASCO 2026
Akeso’s global Phase III HARMONi‑6 trial compared ivodescimab plus chemotherapy with Tevimbra plus chemotherapy in 532 patients with first‑line squamous non‑small cell lung cancer. The study met its primary overall‑survival endpoint, showing a 34% reduction in death risk (median OS 27.9 months...
Global Policy Gaps Slow Biosimilar Adoption and Access
A new UCSF study published in JAMA Health Forum reveals that biosimilar regulations vary widely across 19 countries, hindering their development and market uptake. While biologics represent only about 5% of prescriptions, they account for more than half of drug...
Justicia Carnea Extract Alleviates Oxidative Stress in Pancreatitis
Researchers evaluated ethanol extracts of Justicia carnea leaves in a mouse model of chronic pancreatitis induced by TNBS. Oral administration of 200 mg/kg or 400 mg/kg extract restored antioxidant enzyme levels, lowered oxidative stress markers, and preserved pancreatic glucagon expression. The higher...
Controversial Gene Therapy for Alzheimer’s Disease
Advanced Science News highlighted three breakthrough biotech applications. An AI‑powered wearable headband uses a brain‑computer interface and mindfulness cues to alleviate car sickness, reporting up to 60% symptom reduction. Researchers demonstrated vitrification techniques that preserve Anopheles gambiae mosquito larvae for...
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) From Phase I/II Study in Heavily Pretreated mCRPC...
MHB088C, a B7‑H3‑targeted antibody‑drug conjugate from Minghui Pharmaceutical, presented updated Phase I/II data in heavily pretreated metastatic castration‑resistant prostate cancer (mCRPC) at the 2026 ASCO Annual Meeting. Among 59 enrolled patients, median radiographic progression‑free survival was not reached, with a...
Biohaven Looks to Obesity to Bounce Back From Run of Clinical and Regulatory Failures
Biohaven is repurposing its myostatin‑activin blocker taldefgrobep alfa for obesity after a failed Phase 3 spinal muscular atrophy trial. The drug showed weight‑loss benefits while preserving lean muscle and bone density, prompting a Phase 2 obesity study that began enrollment in March....
Daily Pill Doubles Survival Time for Pancreatic Cancer Patients
A phase III trial of the oral KRAS inhibitor daraxonrasib showed median overall survival of 13.2 months for advanced pancreatic cancer patients, roughly double the 6.6 months achieved with standard chemotherapy. The study enrolled 500 participants across North America, Europe...
This Discovery Could Change How Often You Need Ozempic Shots
A NIH team published in Nature Metabolism that semaglutide’s weight‑loss power depends on how long it sustains cyclic AMP (cAMP) spikes in the brain’s area postrema. Real‑time imaging of mouse neurons showed some cells keep elevated cAMP for hours while...
Long-Term Leukemia Trial Reveals MRD-Triggered Treatment May Slow or Prevent Relapse
The RELAZA2 trial has released its long‑term data, confirming that azacitidine administered at the first sign of measurable residual disease (MRD) can significantly delay relapse in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). As the world’s first prospective MRD‑triggered...
Experimental Pill Promises New Hope for Deadly Pancreatic Cancer
Researchers reported that the experimental pill daraxonrasib, which blocks mutated KRAS proteins, nearly doubled median survival for patients with advanced pancreatic cancer to 13.2 months versus 6.7 months on chemotherapy. The drug showed fewer severe side effects and improved quality...